Mayo Clinic laboratory and pathology research roundup: June 8
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. Via Neuro-Oncology
Published to PubMed This Week
- Ceramide scores predict cardiovascular risk in the community.
Arteriosclerosis, Thrombotic, Vascular, and Biology
- Proton therapy for breast cancer: A consensus statement from the particle therapy cooperative group (PTCOG) breast cancer subcommittee.
International Journal of Radiation, Oncology, Biology, and Physics
- Lessons from the tragedy of COVID-19 and the absence of an influenza season.
American Journal of Medicine
- IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.
- Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era.
- A new D-Galactose treatment monitoring index for PGM1-CDG.
Journal of Inherited Metabolic Disease
- Biomarkers of endothelial dysfunction in alcoholic hepatitis.
- Synovial fluid α defensin has comparable accuracy to synovial fluid white blood cell count and polymorphonuclear percentage for periprosthetic joint infection diagnosis.
Bone and Joint Journal
- Mass spectrometric analysis of urine from COVID-19 patients for detection of SARS-CoV-2 viral antigen and to study host response.
Journal of Proteome Research
- Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots.